End-of-day quote
Korea S.E.
06:00:00 2024-05-09 pm EDT
|
5-day change
|
1st Jan Change
|
9,340
KRW
|
-5.56%
|
|
-11.89%
|
+113.00%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
681,938
|
773,154
|
776,711
|
378,914
|
365,136
|
331,362
|
Enterprise Value (EV)
1 |
673,937
|
773,776
|
761,260
|
329,473
|
353,255
|
309,032
|
P/E ratio
|
144
x
|
-45.8
x
|
-43.9
x
|
-22.4
x
|
-30.6
x
|
-136
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
14.7
x
|
13.1
x
|
18.1
x
|
8.69
x
|
7.59
x
|
6.16
x
|
EV / Revenue
|
14.5
x
|
13.1
x
|
17.7
x
|
7.56
x
|
7.34
x
|
5.75
x
|
EV / EBITDA
|
-261
x
|
-69.1
x
|
-72
x
|
-35.1
x
|
-56.9
x
|
-851
x
|
EV / FCF
|
-99.7
x
|
-57.5
x
|
-42.1
x
|
-26
x
|
-23.9
x
|
42.4
x
|
FCF Yield
|
-1%
|
-1.74%
|
-2.38%
|
-3.84%
|
-4.19%
|
2.36%
|
Price to Book
|
9.93
x
|
12.1
x
|
8.71
x
|
3.7
x
|
3.04
x
|
2.01
x
|
Nbr of stocks (in thousands)
|
51,809
|
52,922
|
56,989
|
57,371
|
67,485
|
75,567
|
Reference price
2 |
13,163
|
14,609
|
13,629
|
6,605
|
5,411
|
4,385
|
Announcement Date
|
3/21/19
|
3/19/20
|
3/17/21
|
3/18/22
|
3/20/23
|
3/18/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
46,357
|
58,966
|
42,930
|
43,586
|
48,132
|
53,749
|
EBITDA
1 |
-2,585
|
-11,194
|
-10,566
|
-9,386
|
-6,211
|
-363.1
|
EBIT
1 |
-3,057
|
-11,883
|
-11,267
|
-11,087
|
-7,877
|
-8,842
|
Operating Margin
|
-6.6%
|
-20.15%
|
-26.24%
|
-25.44%
|
-16.37%
|
-16.45%
|
Earnings before Tax (EBT)
1 |
3,998
|
-16,732
|
-17,401
|
-17,764
|
-12,104
|
-2,769
|
Net income
1 |
4,575
|
-16,423
|
-16,902
|
-17,197
|
-11,354
|
-2,302
|
Net margin
|
9.87%
|
-27.85%
|
-39.37%
|
-39.46%
|
-23.59%
|
-4.28%
|
EPS
2 |
91.40
|
-318.9
|
-310.1
|
-294.2
|
-176.6
|
-32.13
|
Free Cash Flow
1 |
-6,758
|
-13,464
|
-18,101
|
-12,654
|
-14,800
|
7,288
|
FCF margin
|
-14.58%
|
-22.83%
|
-42.16%
|
-29.03%
|
-30.75%
|
13.56%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/21/19
|
3/19/20
|
3/17/21
|
3/18/22
|
3/20/23
|
3/18/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
-
|
622
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
8,001
|
-
|
15,451
|
49,441
|
11,881
|
22,330
|
Leverage (Debt/EBITDA)
|
-
|
-0.0555
x
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-6,758
|
-13,464
|
-18,101
|
-12,654
|
-14,800
|
7,288
|
ROE (net income / shareholders' equity)
|
6.69%
|
-21.2%
|
-19.7%
|
-15.4%
|
-9.38%
|
-1.85%
|
ROA (Net income/ Total Assets)
|
-2.24%
|
-6.01%
|
-5.39%
|
-4.45%
|
-2.61%
|
-2.85%
|
Assets
1 |
-203,935
|
273,300
|
313,798
|
386,732
|
435,124
|
80,905
|
Book Value Per Share
2 |
1,325
|
1,208
|
1,566
|
1,785
|
1,780
|
2,177
|
Cash Flow per Share
2 |
321.0
|
816.0
|
244.0
|
1,503
|
699.0
|
322.0
|
Capex
1 |
223
|
556
|
85.5
|
823
|
3,396
|
302
|
Capex / Sales
|
0.48%
|
0.94%
|
0.2%
|
1.89%
|
7.06%
|
0.56%
|
Announcement Date
|
3/21/19
|
3/19/20
|
3/17/21
|
3/18/22
|
3/20/23
|
3/18/24
|
|
1st Jan change
|
Capi.
|
---|
| +113.00% | 538M | | +20.94% | 72.78B | | -1.26% | 24.24B | | +5.13% | 8.59B | | +8.25% | 8.38B | | -19.42% | 8.09B | | +5.56% | 4.81B | | +16.83% | 4.32B | | -1.83% | 4.05B | | +26.97% | 3.79B |
Pharmaceuticals Wholesale
|